Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review

1. Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc 2009; 84(10): 917–38.10.4065/84.10.917Search in Google Scholar

2. Boden H, van der Hoeven BL, Karalis I, Schalij MJ, Jukema JW. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. J Intern Med 2012; 271(6): 521–36.10.1111/j.1365-2796.2012.02533.x22340431Search in Google Scholar

3. Patel NK, Elmariah S. Acute Coronary Syndromes. In: Lau JF, Barnes GD, Streiff MB, editors. Anticoagulation Therapy. Cham: Springer International Publishing; 2018. p. 197–216.10.1007/978-3-319-73709-6_10Search in Google Scholar

4. Dhoble A, Anderson HV. Strategies in Acute Coronary Syndrome. In: Lanzer P, editor. Textbook of Catheter-Based Cardiovascular Interventions. Cham: Springer International Publishing; 2018. p. 921–38.10.1007/978-3-319-55994-0_55Search in Google Scholar

5. Bassand JP. Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. Eur Heart J Suppl 2006; 8(suppl G): G35–7.10.1093/eurheartj/sul053Search in Google Scholar

6. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267–315.10.1093/eurheartj/ehv32026320110Search in Google Scholar

7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119–77.10.1093/eurheartj/ehx39328886621Search in Google Scholar

8. Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 2015; 38(2): 197–206.10.1007/s40264-014-0262-8462432225556085Search in Google Scholar

9. Baxter K. (2010). Stockley’s Drug Interactions (9th ed.). London: Pharmaceutical Press.Search in Google Scholar

10. de Lima TAM, de Godoy MF. Drug-drug interactions in prescriptions for hospitalized elderly with Acute Coronary Syndrome. Rev Eletrônica Enferm 2017; 19: a24.Search in Google Scholar

11. Pejčić AV, Janković SM, Davidović G. Drug-drug interactions in patients with acute coronary syndrome across phases of treatment. Intern Emerg Med 2019; 14(3): 411–22.10.1007/s11739-018-1994-830483990Search in Google Scholar

12. Dunn SP, Holmes DR, Moliterno DJ. Drug-drug interactions in cardiovascular catheterizations and interventions. JACC Cardiovasc Interv 2012; 5(12): 1195–208.10.1016/j.jcin.2012.10.00523257367Search in Google Scholar

13. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescr 2012; 35: 85–8.10.18773/austprescr.2012.037Search in Google Scholar

14. Cecchi E. Drug-drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med 2019; 14(3): 345–7.10.1007/s11739-018-02016-w30610439Search in Google Scholar

15. Zeymer U, Mark B, Montalescot G, Thiele H, Zahn R. Influence of morphine on the effect of clopidogrel and prasugrel in patients with ST elevation myocardial infarction. Results of the ETAMI trial. Eur Heart J 2015; 36(Abstract Supplement): 227–8.Search in Google Scholar

16. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015; 8(1): e001593.10.1161/CIRCINTERVENTIONS.114.00159325552565Search in Google Scholar

17. Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol 2016; 221: 567–71.10.1016/j.ijcard.2016.06.20427420579Search in Google Scholar

18. Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost 2016; 116(1): 96–102.10.1160/TH16-02-010227099137Search in Google Scholar

19. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37(3): 245–52.10.1093/eurheartj/ehv547471235126491112Search in Google Scholar

20. Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. JACC Cardiovasc Interv 2015; 8(11): 1457–67.10.1016/j.jcin.2015.02.03026404199Search in Google Scholar

21. Silvain J, Storey RF, Cayla G, Esteve J-B, Dillinger J-G, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116(2): 369–78.10.1160/TH15-12-0944Search in Google Scholar

22. Lapostolle F, van’t Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet J-P, et al. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs 2019; 19(2): 173–83.10.1007/s40256-018-0305-030353444Search in Google Scholar

23. Farag M, Spinthakis N, Srinivasan M, Sullivan K, Well-sted D, Gorog DA. Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size. Thromb Hae-most 2018; 118(3): 601–12.10.1055/s-0038-162989629444530Search in Google Scholar

24. Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012; 32(9): 809–18.10.1002/j.1875-9114.2012.01112.x353196222744772Search in Google Scholar

25. Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown) 2012; 13(12): 783–9.10.2459/JCM.0b013e3283416b6b21252697Search in Google Scholar

26. Valkhoff VE, ’t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011; 33(1): 77–88.10.1111/j.1365-2036.2010.04485.x21083580Search in Google Scholar

27. Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011; 46(1): 39–45.10.1007/s00535-010-0299-020811753Search in Google Scholar

28. Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol 2009; 104(12): 3116–7.10.1038/ajg.2009.52519956146Search in Google Scholar

29. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120(23): 2322–9.10.1161/CIRCULATIONAHA.109.873497281878919933932Search in Google Scholar

30. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937–44.10.1001/jama.2009.26119258584Search in Google Scholar

31. Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 2015; 15(1): 20–5.10.1038/tpj.2014.28428745925001880Search in Google Scholar

32. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction. Clin Cardiol 2010; 33(3): 168–71.10.1002/clc.20721665345620235209Search in Google Scholar

33. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125(8): 978–86.10.1161/CIRCULATIONAHA.111.03291222261200Search in Google Scholar

34. Jackson LR, Peterson ED, McCoy LA, Ju C, Zettler M, Baker BA, et al. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc 2016;5(10).10.1161/JAHA.116.003824512148527792656Search in Google Scholar

35. Zou JJ, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, et al. Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor. PLOS ONE 2014; 9(1): e84985.10.1371/journal.pone.0084985388564724416326Search in Google Scholar

36. Parri MS, Gianetti J, Dushpanova A, Della Pina F, Saracini C, Marcucci R, et al. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol 2013; 167(5): 2177–81.10.1016/j.ijcard.2012.05.08022727972Search in Google Scholar

37. Fernando H, Bassler N, Habersberger J, Sheffield LJ, Sharma R, Dart AM, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011; 9(8): 1582–9.10.1111/j.1538-7836.2011.04414.x21696537Search in Google Scholar

38. Chyrchel B, Surdacki A, Chyrchel M, Dudek D, Dubiel JS. Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy. Int J Cardiol 2011; 149(1): 124–5.10.1016/j.ijcard.2011.01.09121345502Search in Google Scholar

39. Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocar-dial infarction evaluating the clopidogrel–PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23(5): 396–404.10.1097/MEG.0b013e328346011021464720Search in Google Scholar

40. Ren Y, Zhao M, Chen Y, Chen L, Liu H, Wang Y, et al. Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl) 2011; 124(6): 856–61.Search in Google Scholar

41. Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J Cardiol 2011; 57(3): 275–82.10.1016/j.jjcc.2011.01.00321371863Search in Google Scholar

42. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13): 1149–53.10.1016/j.jacc.2009.05.05019761935Search in Google Scholar

43. Zhang J, Wang D, Du J, Qu G, Du J, Deng S, et al. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore) 2015; 94(50): e2262.10.1097/MD.0000000000002262505892126683949Search in Google Scholar

44. Liu LP, Wang Y, Si R, Yuan M, Cheng K, Guo WY. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case–control study. Expert Opin Pharmacother 2016; 17(1): 7–16.10.1517/14656566.2016.111014526549402Search in Google Scholar

45. Lu F, Tong Z, Mao Y, Wu D, Xu J. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29(4): 478–81.Search in Google Scholar

46. Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J 2012; 76(11): 2673–80.10.1253/circj.CJ-12-051122864179Search in Google Scholar

47. Bolek T, Samoš M, Šimonová R, Kovář F, Fedor M, Galajda P, et al. Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pilot Prospective Study. Am J Ther 2017; 24(2): e162–6.10.1097/MJT.000000000000045427415979Search in Google Scholar

48. Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol 2012; 74(5): 824–34.10.1111/j.1365-2125.2012.04250.x349514722364155Search in Google Scholar

49. Macaione F, Montaina C, Evola S, Novo G, Novo S. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol 2012; 2012: 692761.10.5402/2012/692761339193622792485Search in Google Scholar

50. Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, et al. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012; 76(1): 71–8.10.1253/circj.CJ-11-069922130313Search in Google Scholar

51. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011; 20(10): 1043–9.10.1002/pds.220221823195Search in Google Scholar

52. Douglas IJ, Evans SJW, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012; 345: e4388.10.1136/bmj.e4388339295622782731Search in Google Scholar

53. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123(5): 474–82.10.1161/CIRCULATIONAHA.110.96564021262992Search in Google Scholar

54. Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira MA, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010; 29(10): 1511–20.Search in Google Scholar

55. Amariles P, Holguín H, Angulo NY, Betancourth PM, Ceballos M. [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. Aten Primaria 2014; 46(8): 426–32.10.1016/j.aprim.2013.11.007698560424581893Search in Google Scholar

56. Gao QP, Sun Y, Sun YX, Wang LF, Fu L. Early use of omeprazole benefits patients with acute myocardial infarction. J Thromb Thrombolysis 2009; 28(3): 282–7.10.1007/s11239-008-0282-218830566Search in Google Scholar

57. Wu H, Jing Q, Wang J, Guo X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care 2011; 26(4): 434.e1–6.10.1016/j.jcrc.2010.12.00721273036Search in Google Scholar

58. Aradi D, Kuliczkowski W, Atar D, Serebruany VL. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Hae-most 2012; 107(2): 338–45.10.1160/TH11-09-062222186910Search in Google Scholar

59. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.10.1136/bmj.d2690309252021562004Search in Google Scholar

60. Kasprzak M, Koziński M, Bielis L, Boinska J, Plazuk W, Marciniak A, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16(6): 535–44.Search in Google Scholar

61. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005; 32(8): 1589–93.Search in Google Scholar

62. Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 2015; 313(8): 805–14.10.1001/jama.2015.080925710657Search in Google Scholar

63. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327(7427): 1322–3.10.1136/bmj.327.7427.132228631914656840Search in Google Scholar

64. Lindvall G, Sartipy U, Bjessmo S, Svenarud P, Lindvall B, van der Linden J. Aprotinin reduces the antiplatelet effect of clopidogrel. Interact Cardiovasc Thorac Surg 2009; 9(2): 178–81.10.1510/icvts.2009.20634219477870Search in Google Scholar

65. Wang CY, Lin ZF, Lee CM, Tsai YW, Huang TY, Shen LJ, et al. Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome. Pharmacoepidemiol Drug Saf 2017; 26(3): 229–38.10.1002/pds.414728067454Search in Google Scholar

66. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2013; 6(12): 1275–81.10.1016/j.jcin.2013.06.01424239201Search in Google Scholar

67. Olesen JB, Gislason GH, Charlot MG, Fosbøl EL, Andersson C, Weeke P, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011; 57(4): 409–17.10.1016/j.jacc.2010.08.64021251580Search in Google Scholar

68. Thotakura S, Singh A, Khera K, Chauhan S, Devasia T. Atorvastatin-induced hepatotoxicity, increased by clopidogrel stress on CYP450 Enzyme: Understanding the mechanism through a case. J Appl Pharm Sci 2018; 8(4): 168–170.10.7324/JAPS.2018.8424Search in Google Scholar

69. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes. Circulation. 2004; 109(11): 1335–8.10.1161/01.CIR.0000124581.18191.1515023882Search in Google Scholar

70. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J 2008; 155(5): 954–8.10.1016/j.ahj.2007.12.00918440347Search in Google Scholar

71. Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G, Kline-Rogers EM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005; 26(11): 1063–9.10.1093/eurheartj/ehi139Search in Google Scholar

72. Han Y, Li C, Li Y, Kang J, Yan C. [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35(9): 788–92.Search in Google Scholar

73. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart Br Card Soc 2005; 91(1): 23–6.10.1136/hrt.2004.035014Search in Google Scholar

74. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92(3): 285–8.10.1016/S0002-9149(03)00626-XSearch in Google Scholar

75. Pourdjabbar A, Hibbert B, Chong AY, Abunassar J, Malhotra N, Whitten TA, et al. A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes. Int J Cardiol 2016; 214: 423–5.10.1016/j.ijcard.2016.03.153Search in Google Scholar

76. Romeo F, Rosano GM, Martuscelli E, De Luca F, Bianco C, Colistra C, et al. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J 1995; 130(4): 692–7.10.1016/0002-8703(95)90065-9Search in Google Scholar

77. Nicolini FA, Ferrini D, Ottani F, Galvani M, Ronchi A, Behrens PH, et al. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. Am J Cardiol 1994; 74(7): 662–6.10.1016/0002-9149(94)90306-9Search in Google Scholar

78. Becker RC, Corrao JM, Bovill EG, Gore JM, Baker SP, Miller ML, et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990; 119(6): 1254–61.10.1016/S0002-8703(05)80172-3Search in Google Scholar

79. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. Arch Intern Med 1987; 147(5): 857–60.10.1001/archinte.1987.00370050053009Search in Google Scholar

80. Gonzalez ER, Jones HD, Graham S, Elswick RK. Assessment of the drug interaction between intravenous nitroglycerin and heparin. Ann Pharmacother 1992; 26(12): 1512–4.10.1177/1060028092026012031482804Search in Google Scholar

81. Nottestad SY, Mascette AM. Nitroglycerin-induced heparin resistance: absence of interaction at clinically relevant doses. Mil Med 1994; 159(8): 569–71.10.1093/milmed/159.8.569Search in Google Scholar

82. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502.10.1056/NEJMoa01074611519503Search in Google Scholar

83. Gille J, Bernotat J, Böhm S, Behrens P, Löhr JF. Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Z Rheumatol 2003; 62(1): 80–1.10.1007/s00393-003-0420-312624808Search in Google Scholar

84. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110(10): 1202–8.10.1161/01.CIR.0000140675.85342.1B15313956Search in Google Scholar

85. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372(19): 1791–800.10.1056/NEJMoa150085725773268Search in Google Scholar

86. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001–15.10.1056/NEJMoa070648217982182Search in Google Scholar

87. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045–57.10.1056/NEJMoa090432719717846Search in Google Scholar

88. Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, et al. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol 2015; 115(10): 1325–32.10.1016/j.amjcard.2015.02.04325776457Search in Google Scholar

89. Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, et al. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. Circulation 2015; 132(20): 1871–9.10.1161/CIRCULATIONAHA.114.01504226338971Search in Google Scholar

90. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J 2014; 168(6): 869–77.e1.10.1016/j.ahj.2014.09.00225458650Search in Google Scholar

91. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, et al. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. J Am Coll Cardiol 2015; 66(7): 777–87.10.1016/j.jacc.2015.06.02726271059Search in Google Scholar

92. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001; 37(2): 475–84.10.1016/S0735-1097(00)01118-9Search in Google Scholar

93. Sámóczi M, Farkas A, Sipos E, Tarján J. [Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina]. Orv Hetil 1995; 136(4): 177–9.Search in Google Scholar

94. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005; 165(7): 784–9.10.1001/archinte.165.7.784Search in Google Scholar

95. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374(9706): 1967–74.10.1016/S0140-6736(09)61751-7Search in Google Scholar

96. Stiles MK, Dabbous OH, Fox KAA, GRACE investigators. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE). Heart Lung Circ 2008; 17(1): 5–8.10.1016/j.hlc.2007.02.09617419100Search in Google Scholar

97. Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, et al. Long-Term Clinical Outcomes of Platelet Glycoprotein IIb/IIIa Inhibitor Combined With Low Molecular Weight Heparin in Patients With Acute Coronary Syndrome. Circ J 2005; 69(2): 159–64.10.1253/circj.69.15915671606Search in Google Scholar

98. Savonitto S, Armstrong PW, Lincoff AM, Jia G, Sila CA, Booth J, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003; 24(20): 1807–14.10.1016/j.ehj.2003.07.00414563339Search in Google Scholar

99. Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006; 152(4): 684.e1–9.10.1016/j.ahj.2006.07.00516996833Search in Google Scholar

100. Amissah-Arthur KN, Groppe M, Scotcher S. Orbital subperiosteal hematoma after thrombolysis and anticoagulation for acute myocardial infarction. J Neuroophthalmol 2009; 29(3): 250–1.10.1097/WNO.0b013e3181b56a3d19726950Search in Google Scholar

101. Ganeva M, Gancheva T, Baldaranov I, Troeva J, Hristakieva E. Screening for adverse drug interactions in dermatology patients. Trakia J Sci 2010; 8(2): 266–71.Search in Google Scholar

102. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183(16): 1835–43.10.1503/cmaj.100912321645521948719Search in Google Scholar

103. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol 2016; 7: 494.10.3389/fphar.2016.00494516525128066243Search in Google Scholar

104. Tseng AL, Luetkehoelter J, Walmsley SL. Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. AIDS 2017; 31(1): 175–6.10.1097/QAD.000000000000127527898595Search in Google Scholar

105. van Sloten TT, de Klaver PAG, van den Wall Bake AWL. Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man. Br J Clin Pharmacol 2018; 84(1): 208–10.10.1111/bcp.13433573685028891590Search in Google Scholar

106. Zhang C, Shen L, Cui M, Liu X, Gu Z. Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report. Medicine (Baltimore) 2017; 96(37): e8065.10.1097/MD.0000000000008065560467328906404Search in Google Scholar

107. Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, et al. Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study. Clin Pharmacol Ther 2014; 96(6): 713–22.10.1038/clpt.2014.18325222620Search in Google Scholar

108. Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep 2017; 18: 1238–41.10.12659/AJCR.905974570826129167415Search in Google Scholar

109. Kido K, Wheeler MB, Seratnahaei A, Bailey A, Bain JA. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc 2015; 55(3): 320–3.10.1331/JAPhA.2015.1415126003161Search in Google Scholar

110. Banakh I, Haji K, Kung R, Gupta S, Tiruvoipati R. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case Rep Crit Care 2017; 2017: 3801819.10.1155/2017/3801819546311228630772Search in Google Scholar

111. van Vuren AJ, de Jong B, Bootsma HPR, Van der Veen MJ, Feith GW. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015; 73(3): 136–8.Search in Google Scholar

112. Cenjor Martín R, Gutiérrez-Madrid E, Martín-Sánchez FJ, Cuervo Pinto R. [Iatrogenic rhabdomyolysis in a patient with ischemic heart disease]. Med Clin (Barc). 2016; 146(10): e57–8.10.1016/j.medcle.2016.06.045Search in Google Scholar

113. Jozic T, Terzic B, Mitrovic P, Kostic J, Milanov M, Stojanovic M, et al. Combined statin-fibrate therapy-induced rhabdomyolysis: Case report. Hospital Pharmacology - International Multidisciplinary Journal 2014; 1(1): 22–6.10.5937/hpimj1401022JSearch in Google Scholar

114. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112(3): 228–30.10.7326/0003-4819-112-3-2282297197Search in Google Scholar

115. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89(1): 117–8.10.1159/00004605611528245Search in Google Scholar

116. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 2010; 48(12): 798–802.10.5414/CPP48798Search in Google Scholar

117. Tada T, Nakata J, Sugawara H, Nishizawa K, Sunaga D, Sato K, et al. [Case report; Selective serotonin reuptake inhibitor induced QT prolongation and ventricular fibrillation in acute myocardial infarction]. Nihon Naika Gakkai Zasshi 2014; 103(3): 738–40.10.2169/naika.103.738Search in Google Scholar

118. Vural M. [Role of the drug interaction between carve-dilol and dobutamine in inducing of severe hypotension in a case with acute coronary syndrome]. Anadolu Kardiyol Derg 2007; 7(2): 229.Search in Google Scholar

119. Fareed FN, Chan G, Hoffman RS. Death temporally related to the use of a Beta adrenergic receptor antagonist in cocaine associated myocardial infarction. J Med Toxicol 2007; 3(4): 169–72.10.1007/BF03160934Search in Google Scholar

120. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008; 64(3): 275–82.10.1007/s00228-007-0404-3Search in Google Scholar

121. Bebawi E, Jouni SS, Tessier A-A, Frenette AJ, Brindamour D, Doré M. A metoprolol-terbinafine combination induced bradycardia. Eur J Drug Metab Pharmacokinet 2015; 40(3): 295–9.10.1007/s13318-014-0205-xSearch in Google Scholar

122. Alsindi A, Murphy C, Martin D. Amiodarone-induced torsades de pointes in a patient with HIV on combination antiretroviral therapy. Grand Rounds 2010; 10: 28–33.Search in Google Scholar

123. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149(6): 1378–1380.e1.10.1053/j.gastro.2015.07.051Search in Google Scholar

124. Kessler KM, Interian A, Cox M, Topaz O, De Marchena EJ, Myerburg RJ. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. Am Heart J 1989; 117(4): 964–6.10.1016/0002-8703(89)90637-6Search in Google Scholar

125. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Study II (CONSENSUS II). Am J Cardiol 1997; 79(2): 115–9.10.1016/S0002-9149(96)00696-0Search in Google Scholar

126. Latini R, Santoro E, Masson S, Tavazzi L, Maggioni AP, Franzosi MG, et al. Aspirin does not interact with ACE inhibitors when both are given early after acute myocar-dial infarction: results of the GISSI-3 Trial. Heart Dis 2000; 2(3): 185–90.Search in Google Scholar

127. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81(10): 1178–81.10.1016/S0002-9149(98)00153-2Search in Google Scholar

128. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10): 669–77.10.1056/NEJM1992090332710011386652Search in Google Scholar

129. Krumholz HM, Chen YT, Wang Y, Radford MJ. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocar-dial infarction. Arch Intern Med 2001; 161(4): 538–44.10.1001/archinte.161.4.53811252112Search in Google Scholar

130. Hanna ER, Clark JA. Serotonin syndrome after cardio-pulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors. Case Rep 2014; 2(9): 113–4.10.1213/XAA.0000000000000010Search in Google Scholar

131. Kelesidis T, Kelesidis I. Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clin Ther 2009; 31(12): 2894–9.10.1016/j.clinthera.2009.12.008805633220110028Search in Google Scholar

132. Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014; 12(1): 2–13.10.1111/jth.1244524406062Search in Google Scholar

133. Khan SU, Lone AN, Asad ZUA, Rahman H, Khan MS, Saleem MA, et al. Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease. Cardiovasc Revasc Med [In press] doi: 10.1016/j.carrev.2019.02.00210.1016/j.carrev.2019.02.002748946330773427Search in Google Scholar

134. Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther 2012; 30(5): e227-233.10.1111/j.1755-5922.2011.00289.x21884023Search in Google Scholar

135. Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes 2015; 8(1): 47–55.10.1161/CIRCOUTCOMES.114.001177614313825587094Search in Google Scholar

136. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–60.10.1093/eurheartj/ehx41928886622Search in Google Scholar

137. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocar-dial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Survival Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134(10): e123–55.10.1161/CIR.0000000000000404Search in Google Scholar

138. D’Ugo E, Rossi S, De Caterina R. Proton pump inhibitors and clopidogrel: an association to avoid? Intern Emerg Med 2014; 9(1): 11–22.10.1007/s11739-013-1000-4Search in Google Scholar

139. Food and Drug Administration U.S. Department of Health and Human Services. Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 2007; 21(2): 73–4.10.1080/J354v21n02_14Search in Google Scholar

140. Ghadban R, Enezate T, Payne J, Allaham H, Halawa A, Fong HK, et al. The safety of morphine use in acute coronary syndrome: a meta-analysis. Heart Asia 2019; 11(1): e011142.10.1136/heartasia-2018-011142645432731031833Search in Google Scholar

141. Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201–8.10.1016/j.ijcard.2016.04.07727128531Search in Google Scholar

142. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32(15): 1854–64.10.1093/eurheartj/ehr20421715717Search in Google Scholar

143. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134(21): e468–95.10.1161/CIR.0000000000000456Search in Google Scholar

144. Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018; 78: 1105–12.10.1007/s40265-018-0947-xSearch in Google Scholar

145. Takkouche B, Etminan M, Caamaño F, Rochon PA. Interaction Between Aspirin and ACE Inhibitors. Drug Saf 2002; 25(5): 373–8.10.2165/00002018-200225050-00005Search in Google Scholar

146. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G, SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dys-function after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35(7): 416–23.10.1002/clc.22017Search in Google Scholar

147. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368(9535): 581–8.10.1016/S0140-6736(06)69201-5Search in Google Scholar